Interviewed two UK longevity clinic doctors about their CJC-1295/Ipamorelin protocols. Both emphasised that the growth hormone secretagogue combination only makes sense for men over 40 with confirmed IGF-1 decline on bloodwork — not as a general performance enhancer. One clinic reported that 60% of enquiries came from men under 35 who had no clinical indication and would see minimal benefit.
A Note Before We Start
CJC-1295 and Ipamorelin are not licensed medications in the UK. They are research peptides, legal to purchase for research purposes. They are prescribed off-label by some private UK clinics in the context of a doctor-supervised protocol. They are not available on the NHS. This guide is educational, it is not a prescription or a recommendation to self-administer any compound without medical oversight.
With that said: these peptides are increasingly used under medical supervision, the mechanism is well-understood from clinical research, and the information vacuum in this space is filled with forum misinformation. A proper explanation is warranted.
Harman et al. (2001) - Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels
Growth hormone and IGF-1 decline progressively with age alongside testosterone - but supplementation only shows clinical benefit in men with confirmed deficiency, not in those with normal levels.
What Growth Hormone Does and Why It Declines
Growth hormone (GH) is produced in the pituitary gland and peaks during adolescence and early adulthood. After 30, GH output declines roughly 15% per decade. By 40, most men are producing significantly less GH than at 25. By 60, GH output may be 25–30% of peak levels.
GH doesn't just make you taller as a child. In adults, it:
- Regulates body composition (promotes fat mobilisation, particularly visceral fat)
- Supports muscle protein synthesis alongside testosterone
- Improves sleep quality, particularly slow-wave deep sleep
- Supports connective tissue repair (tendons, ligaments)
- Has cognitive effects (clarity, memory consolidation during sleep)
- Plays a role in cardiovascular health
The decline of GH with age contributes to: body fat accumulation (especially abdominal), reduced recovery, decreased sleep quality, declining skin integrity, and reduced vitality, a pattern that overlaps substantially with testosterone decline and is often occurring simultaneously.
What CJC-1295 and Ipamorelin Are
Both are growth hormone secretagogues, compounds that stimulate your own pituitary to produce and release more GH. They don't replace GH; they prompt your body to make more of it.
CJC-1295 (Modified GRF 1-29) is a synthetic analogue of Growth Hormone Releasing Hormone (GHRH). GHRH is the hypothalamic signal that tells the pituitary "release growth hormone now." CJC-1295 mimics this signal, with modifications that extend its half-life (how long it remains active before breakdown).
There are two versions:
- CJC-1295 without DAC (also called Modified GRF 1-29), shorter acting (half-life ~30 minutes), produces a pulse of GH that mimics the natural pulsatile secretion pattern
- CJC-1295 with DAC (Drug Affinity Complex), much longer acting (half-life 6–8 days), produces a more sustained elevation of baseline GH
The "without DAC" version is generally preferred in clinical protocols because it preserves the natural pulsatile GH rhythm, which is important for receptor sensitivity and avoiding the desensitisation that constant GH elevation can produce.
Ipamorelin is a synthetic ghrelin mimetic, it activates the growth hormone secretagogue receptor (GHS-R) to trigger GH release. Unlike older compounds in the same class (GHRP-2, GHRP-6), Ipamorelin is highly selective, it stimulates GH release without significant elevation of cortisol or prolactin. This selectivity is why it became the preferred GHRP in modern clinical protocols.
Why They're Used Together
CJC-1295 (GHRH analogue) and Ipamorelin (ghrelin mimetic) work through different receptor pathways that are synergistic. Using both together produces a GH pulse that is significantly larger than either alone, the two mechanisms amplify each other.
This is why the combination is the standard protocol when peptides are used for GH optimisation. Using either alone is less efficient.
What the Research and Clinical Use Shows
The clinical evidence base for growth hormone secretagogues in healthy, non-deficient adults is smaller than for drugs with full pharmaceutical approval. However:
CJC-1295 clinical studies (several Phase I/II trials with Tesamorelin, a closely related GHRH analogue that is approved for HIV-related lipodystrophy) show consistent GH and IGF-1 increases, with visceral fat reduction being the most robust measured outcome.
Ipamorelin human studies confirm selective GH release without significant cortisol or prolactin elevation, the safety advantage over earlier compounds.
Clinical protocol outcomes reported in private practice:
- Improved sleep quality, particularly deep sleep stages (commonly reported within 2–4 weeks)
- Body composition improvement, visceral fat reduction, modest lean mass support (over 3–6 months)
- Improved recovery from training
- Skin quality improvement (increased collagen synthesis)
- Improved morning energy and cognitive clarity
The effects are not dramatic on the timescale of anabolic steroids. This is not a physique-transformation tool in the short term. It is a recovery and body composition optimisation tool with a meaningful cumulative effect over 3–6 months of consistent use.
Protocol Basics
Standard protocol:
- CJC-1295 (without DAC): 100–300mcg per injection
- Ipamorelin: 100–300mcg per injection
- Combined in the same subcutaneous injection
- Typically administered 1–2× daily, with the most important injection being before sleep
Why before sleep: GH naturally pulses most significantly in the first 2 hours of deep sleep. Administering GH secretagogues before sleep amplifies this natural peak, supporting the sleep-recovery-testosterone cascade rather than disrupting it.
Second injection (if used): Either in the morning on waking (fasted) or 45–60 minutes before training. The pre-training injection may improve recovery and the anabolic environment around the session.
Fasted state: GH secretagogues are most effective in a fasted state. Insulin suppresses GH release. The bedtime injection should be administered at least 2–3 hours after the last meal. A carbohydrate-heavy meal immediately before bed significantly blunts the GH response.
Cycle: Many protocols run 3–6 months on, 1–2 months off. Continuous use carries a theoretical risk of receptor desensitisation over the very long term, though the evidence for this with pulsatile protocols is not conclusive.
Sourcing in the UK
This is the area where the information ecosystem is most unreliable. In the UK:
- Peptides classified as research chemicals can be purchased from certain suppliers for research purposes
- Some private UK clinics prescribe growth hormone secretagogues as part of supervised longevity/optimisation protocols
- Quality varies dramatically between sources, verified third-party tested peptides vs unverified products from grey-market sources
The only sensible approach for a UK man considering these peptides: access them through a private doctor/clinic that handles prescribing and sourcing, not through grey-market research chemical suppliers. The clinical supervision adds cost and friction but provides:
- Verified purity (third-party tested)
- Appropriate dosing guidance
- Blood monitoring (IGF-1 to confirm GH elevation, management of any side effects)
- Legal clarity
Some UK clinics that provide TRT (Optimale, Balance My Hormones) also offer peptide protocols. This is the recommended route.
Monitoring: IGF-1
The practical way to confirm that CJC-1295/Ipamorelin is working is an IGF-1 blood test. IGF-1 (Insulin-like Growth Factor 1) is produced in the liver in response to GH and is a stable surrogate marker for GH activity (GH itself fluctuates too rapidly for a single blood test to be meaningful).
A baseline IGF-1 before starting, then a follow-up after 8–12 weeks of protocol, shows whether the peptide combination is producing the expected GH elevation.
Target range: IGF-1 in the upper quarter of the reference range for age is the general target. Excessive IGF-1 elevation is associated with risks (see side effects); the goal is optimisation within normal physiological parameters, not supraphysiological elevation.
Medichecks offers an IGF-1 test for approximately £39.
Side Effects and Risks
Water retention: GH elevation causes water retention, particularly in the early weeks. Typically mild and resolves after 2–4 weeks of consistent use. Can cause transient joint discomfort (carpal tunnel-type symptoms, wrist/hand tingling) that usually self-resolves.
Hypoglycaemia: Both compounds can lower blood sugar, particularly when administered in a fasted state. The effect is usually mild. Men who are diabetic or have blood sugar regulation issues should not use these without medical oversight.
Cortisol and prolactin: Ipamorelin specifically does not elevate cortisol or prolactin (this is its key advantage over GHRP-2 and GHRP-6). CJC-1295 similarly has no significant cortisol effect.
IGF-1 and cancer risk: Elevated IGF-1 is theoretically associated with increased cell proliferation. There is no human evidence that peptide-induced GH elevation at physiological doses increases cancer risk, but it is a theoretical concern. Men with a personal or strong family history of IGF-1-sensitive cancers (prostate, colorectal, breast) should approach with caution and discuss with a doctor.
Pituitary feedback: The long-term effect on pituitary function from sustained secretagogue use is not fully characterised. Pulsatile protocols are preferred for this reason.
Who This Is For
Growth hormone peptides are most relevant for men over 40 who:
- Are experiencing meaningful age-related GH decline symptoms (poor sleep recovery, body composition changes despite good training and diet)
- Have already addressed the foundational optimisations (sleep, testosterone, supplementation)
- Are working with or willing to work with a private doctor for supervision and monitoring
- Have a long-term view, the benefits accumulate over months, not days
They are not for men looking for a shortcut, not appropriate for self-administration without medical oversight, and not a substitute for the lifestyle foundations that drive recovery.
The Short Version
CJC-1295 and Ipamorelin are growth hormone secretagogues that stimulate your pituitary to produce more of your own GH. Used together before sleep, they amplify the natural overnight GH pulse. Key benefits: improved sleep quality, body composition support, recovery. Access through a private UK clinic, not a grey-market supplier. Monitor with IGF-1 blood tests. Not a first step, address the fundamentals first.
CJC-1295/Ipamorelin is only worth considering for men over 40 with confirmed low IGF-1 on bloodwork — younger men with normal growth hormone levels will see minimal benefit and unnecessary risk.
